AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1[1]. AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants[2].
[1]. Sung-Ju Moon, et al. Compositions containing, methods and uses of antibody-tlr agonist conjugates. Patent WO2020168017A1.[2]. Shelley Erin ACKERMAN, et al. Immunoconjugates targeting pd-l1. Patent WO2020190734A1.